ArticleJournal of inflammation research2025
OPG and TNFR1 as Potential Biomarkers of Inflammation in Older Adults with Acute COVID-19 and Indicators of Frailty in Post-COVID-19: A Pilot Study.
Article in Journal of inflammation research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Older individuals are at high risk for severe COVID-19 and often experience geriatric syndromes as post-COVID-19 sequelae associated with inflammation. Osteoprotegerin (OPG) and Tumor Necrosis Factor Receptor 1 (TNFR1) are emerging as promising biomarkers in inflammation-associated diseases. Here, these and other members of the tumor necrosis factor superfamily (TNFSF) were investigated as potential biomarkers to monitor older adults during acute COVID-19 and post-COVID-19 recovery. Patients and Methods: This study included 75 patients with acute COVID-19, 26 post-COVID-19 (evaluated at 4 and 12 months), 35 healthy donors (HD), and 36 individuals with interstitial lung diseases (ILD), all aged over 60. Plasma levels of 14 soluble TNFSF members were measured using flow cytometry-based multiplex immunoassays and ELISA. Multiple logistic regression and ROC curve analyses were performed to assess the potential of TNFSF members as biomarkers. Results: Flow cytometry revealed significantly higher levels of OPG, BAFF, and APRIL in acute COVID-19 patients than in HD and ILD (p<0.001). Through an ELISA, high levels of OPG (p<0.0001), APRIL (p<0.05), and BAFF (p<0.0001) were confirmed, and TNFR1 (p<0.0001) was also revealed. In this pilot study, OPG and TNFR1 had AUCs >0.90 and were predictive of COVID-19, independent of comorbidities, while BAFF levels were modified by diabetes. Persistently elevated OPG and TNFR1 levels were also observed in post-COVID-19 patients at 4 and 12 months. Notably, OPG levels were higher in frail versus non-frail individuals at both time points (p<0.05), while TNFR1 levels were higher only at 4 months (p<0.05). Conclusion: This evidence indicates that OPG and TNFR1 are potential biomarkers of inflammation during acute COVID-19 and post-COVID-19 among older, mainly frail adults. These findings support their utility in managing post-COVID-19 geriatric frailty syndrome.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.